- Apr 2, 2009
- 5,171
- 13,288
- 67
Study (presented as a poster at last week's SRNT conference) by e-cigarette prohibitionists finds 40% decline in mean daily cigarette consumption (from 14.7 to 8.8) among 43 first time e-cigarette users who weren't interested in quitting smoking, but authors falsely claim tobacco toxicant exposure WAS NOT lowered, that "e-cigs may provide no public health benefit", and that their findings support FDA regulation of e-cigarettes as Modified Risk tobacco Products (which would first require FDA to approve a "deeming" regulation that could/would effective ban e-cigarette sales).
http://www.srnt.org/conferences/2012/pdf/2012_Abstracts_H.pdf (POS3-107 on page 121)
POS3-107
E-CIGARETTE ABUSE LIABILITY: SUBJECTIVE, BEHAVIORAL, AND EXPOSURE
EFFECTS OF SWITCHING
Vaughan W. Rees*, Jonathan Noel, Ilan Behm, and Gregory N. Connolly, Center for
Global tobacco Control, Harvard School of Public Health
BACKGROUND: Electronic cigarettes have been promoted as a safer alternative for
delivering nicotine to smokers. However, the appeal of the e-cigarette (e-cig) may be
limited compared with a conventional cigarette. Abuse liability of e-cig was assessed
among daily smokers using a switching study design. METHODS: Participants (N=
43; 35.4 yrs of age; 70% male) were regular smokers not contemplating quitting,
and were naive to e-cig use. After a 72 hour baseline of usual brand of conventional
cigarette use, subjects were switched for a further 11 days to a commercial e-cig
product. Behavior was monitored throughout the study (smoking diary, phone interview)
and follow-up lab sessions were conducted at Days 11 and 14. Puffing topography,
smoking urges, nicotine withdrawal, sensory perceptions, and drug effect and liking
were measured pre- and post-smoking. Exposure to nicotine was assessed via urinary
cotinine pre- and post-switching. RESULTS: After 14 days, mean cigarettes smoked
per day significantly decreased a relative 40.3% from 14.7 at baseline to 8.8 at Day
14 (paired t-test, p<0.001). Subjects took larger (p=.045) and longer (p=.008) puffs
with the e-cig compared with conventional. Cotinine geometric mean did not differ
significantly from baseline to Day 14 (1535.9 ng/ml vs. 1391.7 ng/ml; p<.001). E-cig
use reduced urges to smoke (p=.046) and withdrawal (p=.046). However, e-cig nicotine
effect (p=.006) and liking (p<.001) were rated significantly lower than the conventional
cigarette. CONCLUSIONS: E-cigarette use reduced smoking urges and withdrawal,
but nicotine effect and liking measures suggested a less optimal e-cig nicotine reward.
While conventional cigarette consumption decreased, complete switching did not occur,
further suggesting limited consumer appeal. These data suggest that e-cigs have lower
abuse liability compared with conventional cigarettes and are likely to be used dually
with conventional cigarettes. The failure to lower exposure to tobacco toxicants, while
maintaining nicotine dependence, suggests that e-cigs may provide no public health
benefit. These findings support FDA regulation of e-cigarettes as Modified Risk Tobacco
Products.
National Cancer Institute grant # RO1-CA-125224.
CORRESPONDING AUTHOR: Vaughan Rees, PhD, Harvard School of Public Health,
Center for Global Tobacco Control, 677 Huntington Ave, Boston, MA 02115, United
States, Phone: 617-496-1395, Email: vrees@hsph.harvard.edu
http://www.srnt.org/conferences/2012/pdf/2012_Abstracts_H.pdf (POS3-107 on page 121)
POS3-107
E-CIGARETTE ABUSE LIABILITY: SUBJECTIVE, BEHAVIORAL, AND EXPOSURE
EFFECTS OF SWITCHING
Vaughan W. Rees*, Jonathan Noel, Ilan Behm, and Gregory N. Connolly, Center for
Global tobacco Control, Harvard School of Public Health
BACKGROUND: Electronic cigarettes have been promoted as a safer alternative for
delivering nicotine to smokers. However, the appeal of the e-cigarette (e-cig) may be
limited compared with a conventional cigarette. Abuse liability of e-cig was assessed
among daily smokers using a switching study design. METHODS: Participants (N=
43; 35.4 yrs of age; 70% male) were regular smokers not contemplating quitting,
and were naive to e-cig use. After a 72 hour baseline of usual brand of conventional
cigarette use, subjects were switched for a further 11 days to a commercial e-cig
product. Behavior was monitored throughout the study (smoking diary, phone interview)
and follow-up lab sessions were conducted at Days 11 and 14. Puffing topography,
smoking urges, nicotine withdrawal, sensory perceptions, and drug effect and liking
were measured pre- and post-smoking. Exposure to nicotine was assessed via urinary
cotinine pre- and post-switching. RESULTS: After 14 days, mean cigarettes smoked
per day significantly decreased a relative 40.3% from 14.7 at baseline to 8.8 at Day
14 (paired t-test, p<0.001). Subjects took larger (p=.045) and longer (p=.008) puffs
with the e-cig compared with conventional. Cotinine geometric mean did not differ
significantly from baseline to Day 14 (1535.9 ng/ml vs. 1391.7 ng/ml; p<.001). E-cig
use reduced urges to smoke (p=.046) and withdrawal (p=.046). However, e-cig nicotine
effect (p=.006) and liking (p<.001) were rated significantly lower than the conventional
cigarette. CONCLUSIONS: E-cigarette use reduced smoking urges and withdrawal,
but nicotine effect and liking measures suggested a less optimal e-cig nicotine reward.
While conventional cigarette consumption decreased, complete switching did not occur,
further suggesting limited consumer appeal. These data suggest that e-cigs have lower
abuse liability compared with conventional cigarettes and are likely to be used dually
with conventional cigarettes. The failure to lower exposure to tobacco toxicants, while
maintaining nicotine dependence, suggests that e-cigs may provide no public health
benefit. These findings support FDA regulation of e-cigarettes as Modified Risk Tobacco
Products.
National Cancer Institute grant # RO1-CA-125224.
CORRESPONDING AUTHOR: Vaughan Rees, PhD, Harvard School of Public Health,
Center for Global Tobacco Control, 677 Huntington Ave, Boston, MA 02115, United
States, Phone: 617-496-1395, Email: vrees@hsph.harvard.edu